Loss of Exclusivity (LOE)

Key facts

Drug protections listed in

FDA Orange Book (patents and exclusivities)

Biologic protections listed in

FDA Purple Book

New chemical entity exclusivity

5 years; generic applications with a patent challenge may be filed after 4

Reference biologic exclusivity

12 years from first licensure, under the BPCIA

Pediatric exclusivity

6 months added to existing patents and exclusivities

What is loss of exclusivity?

Loss of exclusivity is the moment a brand loses the legal barriers that keep copies off the market. Those barriers come from two separate systems: patents granted by the U.S. Patent and Trademark Office and regulatory exclusivities granted by the Food and Drug Administration (FDA).

A product reaches LOE when its last blocking patents and exclusivities have expired, been found invalid or not infringed, or been bypassed by a settlement that licenses earlier entry. The practical LOE date is when a competitor can actually launch, which often differs from the expiry date of any single patent.

How exclusivity is determined

Analysts typically combine these protections to estimate an LOE date:

Litigation shapes timing. A generic applicant that certifies a listed patent is invalid or not infringed (a Paragraph IV certification) can trigger a lawsuit and a 30-month stay of FDA approval, and many cases end in settlements that set a licensed entry date. The Biologics Price Competition and Innovation Act (BPCIA) sets a separate patent dispute process for biosimilars.

• Patents: generally 20 years from filing, with possible patent term extension of up to 5 years for time lost in regulatory review.
• New chemical entity exclusivity: 5 years for a drug with a new active moiety.
• New clinical investigation exclusivity: 3 years for changes, such as a new indication, supported by new clinical studies.
• Orphan drug exclusivity: 7 years for the approved rare disease use.
• Pediatric exclusivity: 6 months added to existing protections after FDA-requested pediatric studies.
• Reference product exclusivity: 12 years from first licensure for biologics.

Why LOE matters

LOE is often the largest revenue event in a brand's life. Once multiple generics launch, prices and brand volume typically fall steeply, while biosimilar uptake has historically been slower and varies by product, payer and site of care.

Brand teams plan LOE years ahead: reallocating field forces, preparing authorized generics, contracting with payers and shifting investment to newer products. Generic and biosimilar makers use LOE dates to choose development targets, payers and pharmacy benefit managers use them to forecast savings, and investors use them to value companies.

LOE is rarely a single date

Protection can end at different times for different strengths, formulations and indications. An extended-release version may stay protected after the original version faces generics, and a generic may launch with a label that omits an indication still covered by a method-of-use patent, a practice known as a section viii carve-out.